AMDL, INC. ANNOUNCES CLOSING OF JADE PHARMACEUTICAL, INC. ACQUISITION

AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced that the acquisition of Jade Pharmaceutical Inc. and its two wholly owned China-based subsidiaries for an aggregate of 2,743,000 post-reverse split (13,715,000 pre-reverse split) shares of AMDL Common Stock. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31488&full=1)